Infections  	Infections  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
immunocompromised  	immunocompromised  	 JJ	B-NP
host 	host 	 NN	I-NP
:  	:  	 :	O
role  	role  	 NN	O
of  	of  	 IN	O
daptomycin  	daptomycin  	 JJ	B-NP
Infections  	Infections  	 NNS	I-NP
in  	in  	 IN	O
immunocompromised  	immunocompromised  	 JJ	B-NP
host  	host  	 NN	I-NP
are  	are  	 VBP	O
increasing  	increasing  	 VBG	O
worldwide 	worldwide 	 NNS	O
.  	.  	 .	O
Definition  	Definition  	 NN	O
of  	of  	 IN	O
immunocompromised  	immunocompromised  	 JJ	B-NP
host  	host  	 NN	I-NP
encompasses  	encompasses  	 VBD	O
a  	a  	 DT	O
number  	number  	 NN	O
of  	of  	 IN	O
different  	different  	 JJ	O
pathologies 	pathologies 	 NN	O
,  	,  	 ,	O
such  	such  	 JJ	O
as  	as  	 IN	O
immune-haematological 	immune-haematological 	 NNP	B-NP
,  	,  	 ,	O
oncological 	oncological 	 NN	B-NP
,  	,  	 ,	O
intensivist 	intensivist 	 NN	B-NP
,  	,  	 ,	O
in  	in  	 IN	O
addition  	addition  	 NN	O
to  	to  	 TO	O
all  	all  	 DT	O
patients  	patients  	 NNS	O
being  	being  	 VBG	O
treated  	treated  	 VBN	O
with  	with  	 IN	O
different  	different  	 JJ	O
monoclonal  	monoclonal  	 JJ	B-NP
antibodies  	antibodies  	 NNS	I-NP
and  	and  	 CC	O
TNF-alfa  	TNF-alfa  	 JJ	B-NP
inhibitors 	inhibitors 	 NN	I-NP
.  	.  	 .	O
Daptomycin  	Daptomycin  	 NNP	B-NP
is  	is  	 VBZ	O
a  	a  	 DT	O
novel  	novel  	 NN	O
lipopeptide  	lipopeptide  	 VBZ	O
antimicrobial  	antimicrobial  	 JJ	B-NP
drug 	drug 	 NN	I-NP
,  	,  	 ,	O
its  	its  	 PRP$	O
activity  	activity  	 NN	O
against  	against  	 IN	O
Gram-positive  	Gram-positive  	 JJ	B-NP
bacteria  	bacteria  	 NNS	I-NP
being  	being  	 VBG	O
rapidly  	rapidly  	 RB	O
cidal 	cidal 	 JJ	O
,  	,  	 ,	O
without  	without  	 IN	O
phenomenon  	phenomenon  	 NN	O
related  	related  	 VBN	O
to  	to  	 TO	O
bacterial  	bacterial  	 JJ	B-NP
lysis 	lysis 	 NN	I-NP
.  	.  	 .	O
Daptmomycin  	Daptmomycin  	 NNP	B-NP
received  	received  	 VBD	I-NP
approval  	approval  	 NN	I-NP
for  	for  	 IN	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
complicated  	complicated  	 JJ	O
skin  	skin  	 NN	O
and  	and  	 CC	O
skin  	skin  	 NN	O
structures  	structures  	 NNS	O
infections 	infections 	 NNS	O
,  	,  	 ,	O
sepsis 	sepsis 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
right  	right  	 JJ	O
side  	side  	 NN	O
endocarditis  	endocarditis  	 VBZ	O
sustained  	sustained  	 VBN	O
by  	by  	 IN	O
S.  	S.  	 NNP	B-NP
aureus 	aureus 	 NN	I-NP
.  	.  	 .	O
This  	This  	 DT	O
article  	article  	 NN	O
will  	will  	 MD	O
focus  	focus  	 VB	O
the  	the  	 DT	O
role  	role  	 NN	O
of  	of  	 IN	O
this  	this  	 DT	O
new  	new  	 JJ	O
drug  	drug  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
severe  	severe  	 JJ	O
infections  	infections  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
immunocompromised  	immunocompromised  	 JJ	B-NP
host 	host 	 NN	I-NP
.  	.  	 .	O
Clinical  	Clinical  	 JJ	B-NP
cases  	cases  	 NNS	I-NP
observed  	observed  	 VBD	O
recently  	recently  	 RB	O
will  	will  	 MD	O
be  	be  	 VB	O
also  	also  	 RB	O
presented 	presented 	 VBN	O
.  	.  	 .	O
